BREAKING! Study Published In JAMA Journal Confirms That AstraZeneca’s COVID-19 Jab Increases Incidences Of Cerebral Venous Thrombosis!
Alarmingly, a new study conducted by Scandinavian researchers that has been published in the peer reviewed JAMA Network Journal has confirmed that AstraZeneca’s COVID-19 jab, AZD1222 increases incidences of cerebral venous thrombosis (CVT)!
The study led by researchers from the Norwegian Institute of Public Health-Norway, Statens Serum Institut-Denmark, Finnish Institute for Health and Welfare-Finland and the University of Copenhagen-Denmark has uncovered findings that could also lead to legal actions against the Pharma giant irrespective of whatever legal bindings it might have had with various stupid governments during the procurement process.
Cerebral venous sinus thrombosis (CVST) is a type of stroke that occurs when a blood clot forms in the brain's venous sinuses. This prevents blood from draining out of the brain. As a result, blood cells may break and leak blood into the brain tissues, forming a hemorrhage that can be fatal or can causes long term serious health debilitating
The study team primary goal was to evaluate the association between the AZD1222, BNT162b2, and mRNA-1273 jabs and subsequent thromboembolic and thrombocytopenic events.
The self-controlled case series used individual-level data from national registries in Norway, Finland, and Denmark. Participants included individuals with hospital contacts because of coronary artery disease, coagulation disorders, or cerebrovascular disease between January 1, 2020, and May 16, 2021.
Relative rate (RR) of hospital contacts for coronary artery disease, coagulation disorders, or cerebrovascular disease in a 28-day period following jabs compared with the control period prior to jabs.
The study team found 265 339 hospital contacts, of whom 112 984 [43%] were for female patients, 246 092 [93%] were for patients born in 1971 or earlier, 116 931 [44%] were for coronary artery disease, 55 445 [21%] were for coagulation disorders, and 92 963 [35%] were for cerebrovascular disease.
Interestingly, in the 28-day period following jabs, there was an increased rate of coronary artery disease following mRNA-1273 jabs (RR, 1.13 [95% CI, 1.02-1.25]), but not following AZD1222 jabs (RR, 0.92 [95% CI, 0.82-1.03]) or BNT162b2 jabs (RR, 0.96 [95% CI, 0.92-0.99]).
There was an observed increased rate of coagulation disorders following all 3 types of jabs (AZD1222: RR, 2.01 [95% CI, 1.75-2.31]; BNT162b2: RR, 1.12 [95% CI, 1.07-1.19]; and mRNA-1273: RR, 1.26 [95% CI, 1.07-1.47]).
There was also an observed increased rate of cerebrovascular disease following all 3 jabs (AZD1222: RR, 1.32 [95% CI, 1.16-1.52]; BNT162b2: RR, 1.09 [95% CI, 1.05-1.13]; and mRNA-1273: RR, 1.21 [95% CI, 1.09-1.35]).
However, significantly for individual diseases within the main outcomes, 2 notably high rates were observed: 12.04 (95% CI, 5.37-26.99) for cerebral venous thrombosis and 4.29 (95% CI, 2.96-6.20) for thrombocytopenia, corresponding to 1.6 (95% CI, 0.6-2.6) and 4.9 (95% CI, 2.9-6.9) excess events per 100 000 doses, respectively, following AZD1222 jabs.
The study findings showed that there was an increased rate of hospital contacts because of coagulation disorders and cerebrovascular disease, especially for thrombocytopenia and cerebral venous thrombosis, following AZD1222 jabs.
rates of several thromboembolic and thrombocytopenic outcomes following BNT162b2 and mRNA-1273 jabs were observed, these increases were less than the rates observed after AZD1222, and sensitivity analyses were not consistent. Confirmatory analysis on the 2 mRNA jabs by other methods are warranted.
This new Scandinavian study has confirmed previous data showing increased rates of cerebral venous thrombosis and thrombocytopenia after the AstraZeneca COVID-19 jabs. https://www.nature.com/articles/s41591-021-01408-4
The research also showed higher rates of several thromboembolic and thrombocytopenic outcomes after the Pfizer and Moderna mRNA jabs, although these increases were less than the rates observed after the AstraZeneca jab, and sensitivity analyses were not consistent.
Lead author Dr Jacob Dag Berild, MD from the Norwegian Institute of Public Health, Oslo, told Thailand Medical News
, "This research confirms what we know from other studies: that the AstraZeneca jabs are associated with the rare but serious side effect of jab-induced immune thrombotic thrombocytopenia."
He added, "Reassuringly, no consistent association was observed between the Pfizer and Moderna mRNA jabs and these rare complications.”
Dr Dag Berild noted that in the current study there was an excess of 1.6 events of cerebral venous thrombosis per 100,000 AstraZeneca jab doses, which is similar to what has been previously reported.
When asked as to how he saw these study findings affecting continued use of these jabs, Dr Dag Berild pointed out that the risk–benefit ratio of the vaccine depends on the risk of contracting COVID-19 and the risk for a severe outcome from COVID-19 weighed against the risk for an adverse event after jabs!
He said, "The European Medicines Agency or EMA has concluded that the overall risk–benefit ratio remains positive for the AstraZeneca jabs, but Norway, Finland, and Denmark no longer use the AstraZeneca jabs in their inoculation programs because of adequate availability of alternative jabs. I think this is a reasonable decision!”
The study team linked individual-level data separately from national population, patient, and jab registers in Norway, Finland, and Denmark. Patient registers were used to identify hospital visits and admissions related to thromboembolic and thrombocytopenic disease in all three countries.
The primary main outcomes were relative rates of coronary artery disease, coagulation disorders, and cerebrovascular disease in the 28-day period after the jabs, compared with the control period prior to jabs.
The study team noted that a strength of this study is the use of registers with full population coverage in three countries with universal healthcare, ensuring equal access to care for all permanent residents. At the end of the study period, from January 1, 2020 to May 16, 2021, more than 5.3 million people in the three countries were jabbed with one or two doses.
The team also said that another strength is the inherent adjustment for time-invariant confounders in the self-controlled case series design, and the resulting control of confounders that can affect the more traditional observational studies when complete data for confounders are not available.
Interestingly, in the 28-day period after jabs, there was an elevated rate of coronary artery disease after the Moderna jabs (relative rate [RR], 1.13), but not after the AstraZeneca (RR, 0.92) or Pfizer (RR, 0.96) jabs.
Also, there was an observed increase in the rate of coagulation disorders after all three types of jabs (AstraZeneca RR, 2.01; Pfizer RR, 1.12; and Moderna RR, 1.26).
Furthermore, there was also an increase in the rate of cerebrovascular disease after all three types of jabs (AstraZeneca RR, 1.32; Pfizer RR, 1.09; and Moderna RR, 1.21).
However, for individual diseases in the main outcomes, two notably high rates were observed after the AstraZeneca jabs, with relative rates of 12.04 for cerebral venous thrombosis and 4.29 for thrombocytopenia, corresponding to 1.6 and 4.9 excess events per 100,000 doses, respectively.
Importantly, the elevated risk after the AstraZeneca jabs was consistent across all three countries and robust in sensitivity analyses.
The study team report that they also observed statistically significant increases in hospital contacts for thrombocytopenic and thromboembolic events after the Pfizer and Moderna jabs. However, the risk was smaller than after the AstraZeneca jabs.
The study team commented, "Additionally, the national estimates varied, increased risk was observed only in the oldest cohorts, and sensitivity analysis checking underlying assumptions of the analyses were not consistent. Therefore, the overall and combined increased relative risks following the Pfizer and Moderna jabs should be interpreted with caution.”
The study team also noted that their results with the AstraZeneca jabs are in line with a comparison of observed and historic rates performed on partly the same population in Norway and Denmark, and also with a Scottish national case–control study. https://pubmed.ncbi.nlm.nih.gov/33952445/
For more on AstraZeneca’s jabs that induces thromboembolic and thrombocytopenic events, keep on logging to Thailand Medical News